.png)
Resilience Announces Long-Term Financing of up to $825 Million to Accelerate CDMO Strategy
New Capital from Oak Hill Advisors to Drive Investment in Go-Forward Manufacturing Operations CINCINNATI--(BUSINESS WIRE)--National Resilience...
BLOG
Read on
%201.png)
Navigating the Evolving Landscape of Fill/Finish: Trends, Challenges, and What’s Ahead
A Q&A with Nithin Stephen As the pharmaceutical and biotech industries continue to innovate at a rapid pace, the demand for fill/finish capabilities...
Leveraging Partnerships to Achieve Cell Therapy Success
What impact can partnerships have in cell therapy commercialization success? Eytan Abraham at Resilience discusses the need for a modernized...
Master Cell Banks: Laying the Foundation to Final Product Success
Consider our top 5 FAQs when it comes to MCBs Master cell banks (MCBs) are a critical starting material that lay the foundation for the scale-up and...
Looking Ahead: What Does the Future Have in Store for Nucleic Acid-Based Therapies?
A Q&A with Aaron Larsen Aaron Larsen is the Technical Head for the Nucleic Acids Franchise with Resilience. He began working with nucleic acids back...
Alachua Biomanufacturing Expansion Video
We are remaking the way medicines are made and that starts with our facilities. At our Alachua, Florida campus, Building G defines the future of our...
.png)
Resilience to Establish Biomanufacturing Partnership with AstraZeneca and Purchase Manufacturing Site
SAN DIEGO--National Resilience, Inc. (Resilience) and AstraZeneca PLC announced today that the companies will establish a long-term biomanufacturing...
Cell Therapy – What Does It Take To Become a Mainstream Option
While cell therapies are still a small segment of therapeutics, the landscape is rapidly changing — with over 1,000 ongoing clinical trials and...
